肺炎治療薬の世界市場レポート 2025年

肺炎治療薬市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は10.7％で、172億6,000万米ドルに成長します。この予測期間における成長は、抗生物質耐性株の増加、高齢化社会における肺炎の発生率の上昇、早期診断のための遠隔医療の拡大、新興市場におけるヘルスケア支出の増加、感染症研究への資金提供の増加、啓発キャンペーンの強化などに起因すると考えられます。この期間に予想される主な動向には、モノクローナル抗体の開発、吸入可能な抗生物質の採用、mRNAベースのワクチンの革新、AIを活用した診断ツール、宿主を標的とした治療法の使用、新規の免疫調節剤、迅速なポイントオブケア診断プラットフォームの進歩などがあります。

肺炎の有病率の増加は、肺炎治療薬市場の成長を促進すると予想されます。肺炎は気嚢に炎症を引き起こす肺感染症で、咳、発熱、呼吸困難などの症状を引き起こします。肺炎の発生率の上昇は、高齢化、大気汚染、喫煙、免疫力の低下、抗菌薬耐性、COVID-19やインフルエンザなどの呼吸器感染症の蔓延などの要因に起因しています。肺炎治療薬は、酸素療法、抗炎症薬、症状管理によって回復をサポートしながら、標的薬剤によって細菌性、ウイルス性、真菌性などの感染症の根本的な原因と闘うように設計されています。例えば、2023年1月にNational Center for Biotechnology Informationが発表したところによると、肺炎は世界中で毎年約1億2,000万人が罹患し、約130万人が死亡しています。小児肺炎による死亡者の80％近くは、発展途上国の2歳未満の小児で発生しています。その結果、肺炎の有病率の増加が肺炎治療薬市場の拡大に拍車をかけています。

肺炎治療薬市場の主要企業は、抗生物質耐性に対処し、患者の予後を改善するために、革新的な薬剤製剤と治療方法に注力しています。抗生物質製剤は、肺炎を含む細菌感染症の治療に重要な役割を果たしています。2024年6月、インドを拠点とする製薬会社Orchid Pharma Limitedは、同じくインドを拠点とする製薬会社Cipla Limitedと共同で、セフェピム-エンメタゾバクタムを発売しました。この抗生物質の組み合わせは、尿路感染症（UTI）や肺炎などの複雑な感染症、特に他の薬剤に耐性のある感染症を治療するために設計されています。耐性菌に対抗することで、より強い抗生物質の必要性を減らしながら、より効果的な治療を可能にします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界肺炎治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の肺炎治療薬市場：成長率分析
• 世界の肺炎治療薬市場の実績：規模と成長, 2019-2024
• 世界の肺炎治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界肺炎治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肺炎治療薬市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物
• ワクチン
• 酸素療法
• 世界の肺炎治療薬市場感染によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 院内肺炎（HAP）
• 市中肺炎（CAP）
• 人工呼吸器関連肺炎（VAP）
• 世界の肺炎治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の肺炎治療薬市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の肺炎治療薬市場、薬物の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 抗ウイルス薬
• 抗真菌薬
• コルチコステロイド
• その他の薬物
• 世界の肺炎治療薬市場、ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺炎球菌ワクチン
• インフルエンザ菌b型（Hib）ワクチン
• インフルエンザワクチン
• その他のワクチン
• 世界の肺炎治療薬市場酸素療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高流量鼻カニューラ（HFNC）
• 非侵襲的換気（NIV）
• 機械的人工呼吸器
• その他の酸素療法

第7章 地域別・国別分析

• 世界の肺炎治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肺炎治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺炎治療薬市場：競合情勢
• 肺炎治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Hikma Pharmaceuticals PLC
• Shionogi & Co. Ltd
• Lupin Limited
• Swedish Orphan Biovitrum AB
• Nabriva Therapeutics plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肺炎治療薬市場2029：新たな機会を提供する国
• 肺炎治療薬市場2029：新たな機会を提供するセグメント
• 肺炎治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pneumonia therapeutics encompass treatments and medications designed to manage and treat pneumonia, a lung infection caused by bacteria, viruses, or fungi. These therapeutics work by targeting the underlying pathogens, reducing inflammation, and improving respiratory function. Treatments include antibiotics for bacterial pneumonia, antiviral drugs for viral pneumonia, and antifungal agents for fungal infections.

The main products in pneumonia therapeutics include drugs, vaccines, and oxygen therapy. Pneumonia drugs address the root cause by using antibiotics, antivirals, antifungals, and supportive treatments such as oxygen therapy. The infections treated include hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP). Routes of administration include oral, parenteral, and other methods, with end users spanning hospitals, home care, specialty clinics, and other healthcare facilities.

The pneumonia therapeutics market research report is one of a series of new reports from The Business Research Company that provides pneumonia therapeutics market statistics, including the pneumonia therapeutics industry's global market size, regional shares, competitors with a pneumonia therapeutics market share, detailed pneumonia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pneumonia therapeutics industry. This pneumonia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pneumonia therapeutics market size has grown rapidly in recent years. It will grow from $10.35 billion in 2024 to $11.49 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to the increasing prevalence of drug-resistant strains, rising awareness of pneumonia prevention, growth in elderly and immunocompromised populations, expanded vaccination programs, and improvements in healthcare infrastructure.

The pneumonia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $17.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the increasing prevalence of antibiotic-resistant strains, the rising incidence of pneumonia in aging populations, the expansion of telemedicine for early diagnosis, growing healthcare expenditures in emerging markets, increased funding for infectious disease research, and heightened awareness campaigns. Key trends expected during this period include the development of monoclonal antibodies, the adoption of inhalable antibiotics, innovations in mRNA-based vaccines, AI-driven diagnostic tools, the use of host-targeted therapies, novel immunomodulators, and advancements in rapid point-of-care diagnostic platforms.

The increasing prevalence of pneumonia is expected to drive the growth of the pneumonia therapeutics market. Pneumonia is a lung infection that causes inflammation in the air sacs, leading to symptoms such as cough, fever, and difficulty breathing. The rising incidence of pneumonia is attributed to factors including aging populations, air pollution, smoking, weakened immune systems, antimicrobial resistance, and the spread of respiratory infections such as COVID-19 and influenza. Pneumonia therapeutics are designed to combat the infection's underlying cause whether bacterial, viral, or fungal through targeted medications while supporting recovery with oxygen therapy, anti-inflammatory drugs, and symptom management. For example, in January 2023, the National Center for Biotechnology Information reported that pneumonia affects approximately 120 million people worldwide each year, resulting in around 1.3 million deaths. Nearly 80% of pediatric pneumonia fatalities occur in children under two years old in developing nations. As a result, the growing prevalence of pneumonia is fueling the expansion of the pneumonia therapeutics market.

Leading companies in the pneumonia therapeutics market are focusing on innovative drug formulations and treatment methods to address antibiotic resistance and enhance patient outcomes. Antibiotic drugs play a crucial role in treating bacterial infections, including pneumonia. In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, collaborated with Cipla Limited, another India-based pharmaceutical firm, to introduce cefepime-enmetazobactam. This antibiotic combination is designed to treat complex infections, such as urinary tract infections (UTIs) and pneumonia, particularly those resistant to other medications. By combating bacterial resistance, it ensures more effective treatment while reducing the need for stronger antibiotics.

In August 2022, GSK plc, a UK-based pharmaceutical company, acquired Affinivax Inc. for an undisclosed amount. This acquisition allows Affinivax to continue its work under GSK's leadership, focusing on next-generation pneumococcal vaccines. Affinivax Inc. is a US-based biopharmaceutical company specializing in developing vaccines to prevent pneumonia and other diseases caused by Streptococcus pneumoniae. This strategic move strengthens GSK's pneumonia vaccine portfolio, reinforcing its position in the market.

Major players in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., and Tergene Biotech Limited.

North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumonia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumonia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumonia therapeutics market consists of revenues earned by entities by providing services such as chest X-rays, blood tests, sputum culture, oxygen supplementation, mechanical ventilation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pneumonia therapeutics market also includes sales of pneumococcal vaccines, antibiotics, nebulizers, and inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values, that is, revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumonia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumonia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pneumonia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumonia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Drugs; Vaccine; Oxygen Therapy
• 2) By Infection: Hospital-Acquired Pneumonia (HAP); Community-Acquired Pneumonia (CAP); Ventilator-Associated Pneumonia (VAP)
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End Use: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Drugs: Antibiotics; Antiviral Drugs; Antifungal Drugs; Corticosteroids; Other Drugs
• 2) By Vaccine: Pneumococcal Vaccines; Haemophilus Influenzae Type B (Hib) Vaccines; Influenza Vaccines; Other Vaccines
• 3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC); Non-Invasive Ventilation (NIV); Mechanical Ventilation; Other Oxygen Therapies
• Companies Mentioned:Pfizer Inc.; Roche AG; Merck & Co. Inc.; AbbVie Inc; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pneumonia Therapeutics Market Characteristics

3. Pneumonia Therapeutics Market Trends And Strategies

4. Pneumonia Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pneumonia Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pneumonia Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pneumonia Therapeutics Market Growth Rate Analysis
• 5.4. Global Pneumonia Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pneumonia Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pneumonia Therapeutics Total Addressable Market (TAM)

6. Pneumonia Therapeutics Market Segmentation

• 6.1. Global Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Vaccine
• Oxygen Therapy
• 6.2. Global Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital-Acquired Pneumonia (HAP)
• Community-Acquired Pneumonia (CAP)
• Ventilator-Associated Pneumonia (VAP)
• 6.3. Global Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.4. Global Pneumonia Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antiviral Drugs
• Antifungal Drugs
• Corticosteroids
• Other Drugs
• 6.6. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pneumococcal Vaccines
• Haemophilus Influenzae Type B (Hib) Vaccines
• Influenza Vaccines
• Other Vaccines
• 6.7. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Oxygen Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Flow Nasal Cannula (HFNC)
• Non-Invasive Ventilation (NIV)
• Mechanical Ventilation
• Other Oxygen Therapies

7. Pneumonia Therapeutics Market Regional And Country Analysis

• 7.1. Global Pneumonia Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pneumonia Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pneumonia Therapeutics Market

• 8.1. Asia-Pacific Pneumonia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pneumonia Therapeutics Market

• 9.1. China Pneumonia Therapeutics Market Overview
• 9.2. China Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pneumonia Therapeutics Market

• 10.1. India Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pneumonia Therapeutics Market

• 11.1. Japan Pneumonia Therapeutics Market Overview
• 11.2. Japan Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pneumonia Therapeutics Market

• 12.1. Australia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pneumonia Therapeutics Market

• 13.1. Indonesia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pneumonia Therapeutics Market

• 14.1. South Korea Pneumonia Therapeutics Market Overview
• 14.2. South Korea Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pneumonia Therapeutics Market

• 15.1. Western Europe Pneumonia Therapeutics Market Overview
• 15.2. Western Europe Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pneumonia Therapeutics Market

• 16.1. UK Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pneumonia Therapeutics Market

• 17.1. Germany Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pneumonia Therapeutics Market

• 18.1. France Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pneumonia Therapeutics Market

• 19.1. Italy Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pneumonia Therapeutics Market

• 20.1. Spain Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pneumonia Therapeutics Market

• 21.1. Eastern Europe Pneumonia Therapeutics Market Overview
• 21.2. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pneumonia Therapeutics Market

• 22.1. Russia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pneumonia Therapeutics Market

• 23.1. North America Pneumonia Therapeutics Market Overview
• 23.2. North America Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pneumonia Therapeutics Market

• 24.1. USA Pneumonia Therapeutics Market Overview
• 24.2. USA Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pneumonia Therapeutics Market

• 25.1. Canada Pneumonia Therapeutics Market Overview
• 25.2. Canada Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pneumonia Therapeutics Market

• 26.1. South America Pneumonia Therapeutics Market Overview
• 26.2. South America Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pneumonia Therapeutics Market

• 27.1. Brazil Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pneumonia Therapeutics Market

• 28.1. Middle East Pneumonia Therapeutics Market Overview
• 28.2. Middle East Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pneumonia Therapeutics Market

• 29.1. Africa Pneumonia Therapeutics Market Overview
• 29.2. Africa Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pneumonia Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Pneumonia Therapeutics Market Competitive Landscape
• 30.2. Pneumonia Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Pneumonia Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca PLC
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GSK plc
• 31.6. Eli Lilly and Company
• 31.7. Astellas Pharma Inc.
• 31.8. Eisai Co. Ltd.
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Cipla Inc.
• 31.11. Hikma Pharmaceuticals PLC
• 31.12. Shionogi & Co. Ltd
• 31.13. Lupin Limited
• 31.14. Swedish Orphan Biovitrum AB
• 31.15. Nabriva Therapeutics plc

32. Global Pneumonia Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pneumonia Therapeutics Market

34. Recent Developments In The Pneumonia Therapeutics Market

35. Pneumonia Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Pneumonia Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pneumonia Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pneumonia Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer